<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104478</url>
  </required_header>
  <id_info>
    <org_study_id>RT3</org_study_id>
    <nct_id>NCT03104478</nct_id>
  </id_info>
  <brief_title>Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)</brief_title>
  <acronym>RT3</acronym>
  <official_title>Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will enroll 194 previously untreated DLBCL patients over 20 months, with the
      objective to send to the local investigator an extensive molecular tumor characterization by
      D38 in at least 80% of enrolled patients.

      The feasibility and efficiency will be demonstrated by deploying and operating a nation-wide
      network of dedicated multidisciplinary platforms.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Real time report of molecular characterization</measure>
    <time_frame>38 days (i.e. 38 days after starting inductive chemotherapy regimen</time_frame>
    <description>To timely report the molecular characterization (pathogenic, diagnostic, prognostic, theranostic markers) of previously untreated DLBCL patients prior to day 38(i.e. 38 days after starting inductive chemotherapy regimen, in at least 80% of enrolled patients</description>
  </primary_outcome>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biological samples collection</intervention_name>
    <description>In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are collected at time of enrollment in the trial.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient ≥ 18 years old with prior untreated DLBCL
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DLBCL patients that will be eligible in front-line treatment for a combination of
             anthracycline-based chemotherapy plus anti-CD20 monoclonal antibody,Rituximab: R-CHOP
             14, R-CHOP 21, R mini-CHOP, R-ACVBP, R-COPADEM. Patients treated with R-CHOP
             associated with an experimental drug ((polatuzumab, tazemetostat, venetoclax,
             entospletinib, lenalidomide, ibrutinib, anti PD1/anti PDL1 ….)

          -  A short corticotherapy (prednisone, maximum 7 days) given during pre-phase therapy is
             allowed.

          -  Eligible histological subtypes: in particular DLBCL NOS, PMBL, high grade B-cell
             lymphoma (HGBCL) withMYC and BCL2 and/or BCL6 rearrangements, HGBCL NOSFL grade 3B and
             untreated transformed low grade NHL.

          -  ≥ 18 years old, IPI = 0-5

          -  With available tumor Biopsy (FFPE) that can be sent to RT3 platform at the time of
             inclusion (or the say after inclusion at the latest).

          -  Patient that underwent needle core biopsy samples are not excluded if sufficient
             material is available for molecular and histopathological explorations

        Exclusion Criteria:

          -  No available FFPE biopsy material or insufficient quality/quantity tumor samples
             according to prerequisite

          -  No signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Jardin, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christiane Copie, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Stephan</last_name>
    <phone>04 72 66 93 33</phone>
    <email>christine.stephan@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gandhi Laurent DAMAJ</last_name>
      <email>damaj-gl@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Gandhi Laurent DAMAJ, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN</last_name>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS</last_name>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Départemental</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé MAISONNEUVE</last_name>
      <email>herve.maisonneuve@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Hervé MAISONNEUVE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Claude Hurriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER</last_name>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>MONTPELLIER Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON</last_name>
      <email>g-cartron@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume CARTRON, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven LE GOUILL</last_name>
      <email>steven.legouill@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Steven LE GOUILL, Porfessor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krimo BOUABDALLAH</last_name>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Krimo BOUABDALLAH, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles SALLES</last_name>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles SALLES, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de la Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DELWAIL</last_name>
      <email>vincent.delwail@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent DELWAIL, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74370</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas DAGUINDAU</last_name>
      <email>ndaguindau@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas DAGUINDAU, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice JARDIN</last_name>
      <email>fabrice.jardin@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice JARDIN, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopôle - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie OBERIC</last_name>
      <email>oberic.l@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Lucie OBERIC, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIERRE FEUGIER</last_name>
      <email>p.feugier@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FEUGIER, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent RIBRAG</last_name>
      <email>vincent.ribrag@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent RIBRAG, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>Real time molecular characterization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

